Results
IBS, sleep disorders, allergies
ALLERGIES
In this study, 136 patients with IBS were included, of which 68 (50%) had sleep disorders, according to the PSQI score. Each group (with and without sleep disorders) was evenly and randomly divided into two subgroups of 34 patients to receive melatonin or placebo. During the trial, patients tolerated supplements well, and no specific side effects or allergies were reported. In addition, all patients had adherence to the trial. Therefore, we did not exclude any patients, and the drop-out rate was 0%.Data did not follow a normal distribution. 62 patients were male (45.5%), and 74 were female (54.5%) Demographic data of the patientsIBS score and GI symptoms at the beginning and end of the trialSleep parameters at the beginning and end of the trialIn the group with sleep disorders, 32 melatonin (94.1%) and 29 placebo recipients (85.3%) had moderate and severe IBS, reduced to 14 (41.2%) and 24 patients (70.6%) at the end of the trial, respectively (In the group without sleep disorders, 29 melatonin (85.3%) and 32 placebo recipients (94.1%) had moderate and severe IBS, reduced to 14 (41.2%) and 26 patients (76.4%) at the end of the trial, respectively (In the group with sleep disorders, 27 melatonin (79.4%) and 24 placebo recipients (70.5%) had fairly and very bad subjective sleep quality, reduced to 6 (17.6%) and 20 patients (58.8%) at the end of the trial, respectively (In the group without sleep disorders, 11 melatonin (32.4%) and 6 placebo recipients (17.6%) had very good subjective sleep quality, increased to 12 (35.3%) and 7 patients (20.6%) at the end of the trial, respectively (